Uses and misuses of treatments for ADHD. The second Birgit Olsson lecture

Nordic Journal of Psychiatry

Volumn 68, Issue 4, 2014, Pages 236-242

  Taylor, Eric ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

ADHD; Cultural differences; Pharmacotherapy

Indexed keywords

CENTRAL STIMULANT AGENT;

ATTENTION DEFICIT DISORDER; DRUG MISUSE; DRUG SAFETY; FOLLOW UP; HUMAN; PRACTICE GUIDELINE; REVIEW; VALIDITY;

ADOLESCENT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; CROSS-CULTURAL COMPARISON; DRUG UTILIZATION; EUROPE; HUMANS; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC;

EID: 84899067227     PISSN: 08039488     EISSN: 15024725     Source Type: Journal    
DOI: 10.3109/08039488.2013.804118     Document Type: Review

References (44)

1. Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA. The worldwide prevalence of ADHD: A systematic review and metaregression analysis. Am J Psychiatry. 2000;164: 942-8.
2. Scheffler RM, Hinshaw SP, Modrek S, Levine P. The global market for ADHD medications. Health Aff (Millwood) 2007;26: 450-57.
3. Hinshaw SP, Scheffler RM, Fulton BD, Aase H, Banaschewski T, Cheng W, et al. International variation in treatment procedures for ADHD: Social context and recent trends. Psychiatr Serv 2011;62: 459-64.
4. Zito JM, Safer DJ, Berg L, Janhsen K, Fegert JM, Gardner JF, et al. A three-country comparison of psychotropic medication prevalence in youth. Child Adolesc Psych Mental Health 2008;2: 26.
5. National Institute for Clinical Excellence 2006 Methylphenidate, atomoxetine and dexamfetamine for the treatment of ADHD in children and adolescents. Technology Appraisal 98. London: NICE. Available at: www.nice.org.uk/TA98.
6. Visser SN, Blumberg SJ, Danielson ML, Bitsko RH, Kogan MD. State-based and demographic variation in parent-reported medication rates for ADHD, 2007-2008. [Erratum appears in Prev Chronic Dis 2013;10. http://www.cdc.gov/pcd/ issues/2013/12-0073e.htm.] Prev Chronic Dis 2013;10: 20073. DOI: http://dx.doi.org/10.5888/pcd9.120073.
7. Trip A-M, Visser ST, Kalverdijk LJ. and De Jong-van den Berg LTW. (2009), Large increase of the use of psycho-stimulants among youth in the Netherlands between 1996 and 2006. Br J Clin Pharmacol 2009;67: 466-8.
8. Knopf H, Hölling H, Huss M, Schlack R. Prevalence, determinants and spectrum of attention-deficit hyperactivity disorder (ADHD) medication of children and adolescents in Germany: Results of the German Health Interview and Examination Survey (KiGGS). BMJ Open;2012;2(6).
9. McCarthy S, Wilton L, Murray ML, Hodgkins P, Asherson P, Wong IC. The epidemiology of pharmacologically treated attention deficit hyperactivity disorder (ADHD) in children, adolescents and adults in UK primary care. BMC Pediatr 2012;12: 78.
10. Knellwolf AL, Deligne J, Chiarotti F, Auleley GR, Palmieri S, Boisgard CB, et al. Prevalence and patterns of methylphenidate use in French children and adolescents. Eur J Clin Pharmacol 2008;64: 311-17.
11. Murray ML, de Vries CS, Wong ICK. A drug utilization study of antidepressants in children and adolescents using the General Practice research Database. Arch Dis Child 2004;89: 1089-102.
12. Olfson M, Blanco C, Liu L, Moreno C, Laje G. National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. Arch Gen Psychiatry 2006;63: 679-85.
13. Patel NC, Crismon ML, Hoagwood K, Johnsrud MT, Rascati KL, Wilson JP et al. Trends in the use of typical and atypical antipsychotics in children and adolescents. J Am Acad Child Adolesc Psychiatry 2005;44: 548-56.
14. Canadian Attention Deficit Hyperactivity Disorder Resource Alliance (CADDRA): Canadian ADHD Practice Guidelines, third edition. Toronto: CADDRA;2011.
15. Taylor E, Doepfner M, Sergeant J, Asherson P, Banaschewski T, Buitelaar J, et al. European clinical guidelines for hyperkinetic disorder - First upgrade. Eur Child Adolesc Psychiatry 2004;Supplement: 13.
16. Scottish Intercollegiate Guidelines Network. Management of attention deficit and hyperkinetic disorders in children and young people. SIGN 2009 Edinburgh. www.sign.ac.uk/guidelines/fulltext/112.
17. National Institute for Clinical Excellence. Attention Deficit Hyperactivity Disorder. Leicester/London: British Psychological Society and The Royal College of Psychiatrists;2009. www.nice.org.uk/CG72.
18. American Academy of Child and Adolescent Psychiatry. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2007;46: 894-921.
19. American Academy of Pediatrics ADHD: Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics 2011;128: 1007-22. www.pediatrics.org/ cgi/doi/10.1542/peds.2011-2654.
20. Rapoport, J. Pediatric psychopharmacology: Too much or too little? World Psychiatry 2013;12: 118-23.
21. Angold A, Erkanli A, Egger HL, Costello EJ. 2000 Stimulant treatment for children: A community perspective. J Am Acad Child Adolesc Psychiatry 2000;39: 975-84.
22. Costello EJ, Mustillo S, Erkanli A, Keeler G, Angold A 2003 Prevalence and development of psychiatric disorders in childhood and adolescence. Arch Gen Psychiatry 2003;60: 837-44.
23. Duncan GJ et al. School readiness and later achievement. Dev Psychol 2007;43: 1428-46.
24. Trzesniewski KH, Moffitt TE, Caspi A, Taylor A, Maughan B. Revisiting the association between reading achievement and antisocial behavior: New evidence of an environmental explanation from a twin study. Child Dev 2006;77: 72-88.
25. Lindeboom M, van den Berg G, von Hinke Kessler Scholder S, Washbrook E. Child mental health problems and youth educational attainment in the UK: Evidence from the Avon Longitudinal Study of Parents and Children. Conference of Epidemiological Longitudinal Studies in Europe (CELSE), Cyprus;2010.
26. Moya J, Stringaris AK, Asherson P, Sandberg S, Taylor, E. The impact of persisting hyperactivity on social relationships: A community-based, controlled 20-year-follow-up study. J Attention Dis. 2014;18: 52-60.
27. Young, S, Taylor E, Gudjonsson G. Childhood predictors of criminal offending: Results from a 19 year longitudinal epidemiological study of boys. J Attention Dis 2012 Nov 29 [Epub ahead of print].
28. Lichtenstein P, Halldner L, Zetterqvist J, Sjolander A, Serlachius E, Fazel S, et al. Medication for attention deficit-hyperactivity disorder and criminality. N Engl J Med 2012;367: 2006-14.
29. Farone SV, Biederman J, Spencer TJ, Aleardi M. Comparing the efficacy of medications for ADHD using meta-analysis. Med Gen Med 2006;8: 4.
30. Sonuga-Barke EJS, Brandeis D, Cortese S, Daley D, Ferrin M, Holtmann M et al Non-pharmacological interventions for ADHD: Systematic review and meta-analyses of randomised controlled trials of dietary and psychological treatments. J Am Psych Assoc 2013;170: 275-89.
31. Graham J, Banaschewski T, Buitelaar J, Coghill D, Danckaerts M, Dittmann RW, et al. (for the European Guidelines Group). European guidelines on managing adverse effects of medication for ADHD. Eur Child Adolesc Psychiatry 2011;20: 17-37.
32. Singh I. Brain talk: Power and negotiation in children's discourse about self, brain and behavior. Sociol Health Illn 2013;35: 813-27.
33. Castellanos FX, Lee PP, Sharp W, Jeffries NO, Greenstein DK, Clasen LS et al. Developmental trajectories of brain volume abnormalities in children and adolescents with ADHD. JAMA 2002;288: 1740-8.
34. Nakao T, Radua J, Rubia K, Mataix-Cols D. Gray matter volume abnormalities in ADHD: Voxel-based meta-analysis exploring the effects of age and stimulant medication. Am J Psychiatry 2011;168: 1154-63.
35. Wilens TE, Morrison NR. The intersection of ADHD and substance abuse. Curr Opin Psychiatry 2011;24: 280-5.
36. Barkley R. Predicting the response of hyperkinetic children to stimulant drugs: A review. J Abn Child Psych 1976;4: 327-48.
37. Buitelaar JK, Van der Gaag RJ, Swaab-Barneveld H, Kuiper M. Prediction of clinical response to methylphenidate in children with ADHD. J Am Acad Child Adolesc Psychiatry 1995;34: 1025-32.
38. Taylor EA, Schachar R, Thorley G, Wieselberg HM, Everitt B, Rutter M. Which boys respond to stimulant medication? A controlled trial of methylphenidate in boys with disruptive behavior. Psych Med;17: 121-43.
39. Cheon KA, Kim BN, Cho SC. Association of 4-repeat allele of the dopamine D4 receptor gene exon III polymorphism and response to methylphenidate treatment in Korean ADHD children. Neuropsycho pharmacology. 2007;32: 1377-83.
40. Arnold LE, Abikoff HB, Cantwell DP, Conners CK, Elliott G, Greenhill LL et al. National Institute of Mental Health collaborative Multimodal Treatment study of children with ADHD (the MTA): Design challenges and choices. Arch Gen Psychiatry 1997;54: 865-70.
41. Santosh PJ, Taylor E, Swanson JM, Wigal T, Chuang S, Davies M et al. Refining the diagnoses of inattention and overactivity syndromes: A reanalysis of the Multimodal Treatment study of ADHD based on ICD-10 criteria for hyperkinetic disorder. Clin Neurosci Res 2005;5: 307-31.
42. Molina BS, Hinshaw SP, Swanson JM, Arnold LE, Vitiello B, Jensen PS et al. The MTA at 8 years: Prospective follow-up of children treated for combined-type ADHD in a multisite study. J Am Acad Child Adolesc Psychiatry 2009;48: 484-500.
43. Academy of Medical Sciences. Brain Science, addiction and drugs. London: Academy of Medical Sciences, 2008. p. 147.
44. Timimi S, Taylor E. ADHD is best understood as a cultural construct. Br J Psychiatry 2004;184: 8-9.